期刊文献+

黄连素对早期糖尿病肾病危险因素的影响 被引量:6

The Influence of Berberine on Dangerous Factors Causing Early Stage of Diabetic Nephropathy
下载PDF
导出
摘要 目的:观察黄连素对早期糖尿病肾病危险因素的影响。方法:选取早期糖尿病肾病患者100例,随机分为试验组和对照组,每组50例。对照组患者进行运动治疗和饮食治疗,试验组患者在对照组的基础上采用黄连素治疗。结果:试验组治疗后BMI、FPG、TC、TG、HOMA-IR、Hb A1C均优于对照组(P<0.05);试验组治疗后BUN、Scr与对照组比较无显著性差异(P>0.05)。结论:黄连素能明显降低早期糖尿病肾病患者的血脂、血糖,改善患者的胰岛素抵抗能力等危险因素。 Objective: To observe the influence of berberine on dangerous factors causing early stage of diabetic nephropathy. Methods: One hundred patients with early stage of diabetic nephropathy were randomly divided into the experiment group and the control group,with 50 cases in each group. The ones in the control group were given movement and diet treatment,while the ones in the experiment group were added berberine based on the treatment of the control group. Results: After the treatment,BMI,FPG,TC,TG,HOMA-IR and Hb A1 C of the experiment group were all better than those of the control group( P〈0. 05). After the treatment,in terms of BUN and Scr,there were no obvious significance between the two groups( P〈0. 05). Conclusion: Berberine can obviously reduce blood fat and blood sugar of patients with early stage of diabetic nephropathy,and improve dangerous factors,for example,insulin resistance,etc.
作者 苏露煜 曹平
出处 《河南中医》 2015年第10期2439-2440,共2页 Henan Traditional Chinese Medicine
基金 陕西省科技厅计划项目(编号:QS061-C33-21)
关键词 早期糖尿病肾病 危险因素 黄连素 治未病 early stage of diabetic nephropathy dangerous factors berberine prevention of disease
  • 相关文献

参考文献9

二级参考文献32

  • 1吕仁和.消渴病(糖尿病)的分期[J].中国中医药现代远程教育,2006,4(2):18-19. 被引量:53
  • 2赵进喜.糖尿病前期的中成药治疗[J].糖尿病新世界,2007(1):34-36. 被引量:17
  • 3金智生,李娟娥,张东鹏.红芪多糖对改善模型大鼠胰岛素抵抗的实验研究[J].中医药通报,2007,6(1):60-62. 被引量:12
  • 4尤金亮.从中医养生角度谈糖尿病的防治[J].河北中医,2007,29(4):321-322. 被引量:1
  • 5Wang J, Song Y, Elsherif L, et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation [J]. Circulation, 2006, 13 (4): 544-554.
  • 6Wei W, Liu Q, Tan Y, et, al. Oxidative stress, diabetes, and diabetic complications [J]. Hemoglobin, 2009, 33 (5): 370-377.
  • 7Ferrara N. Vascular endothelial growth factor: basic science and clinical progress [J]. Endocr Rev, 2004, 25 (4): 581- 611.
  • 8Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis [J]. Clin Oncol, 2005, 23 (5):1011-1027.
  • 9Machado DE, Berardo PT, Palmero CY, et al. Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase 9 (MMP- 9) in a rat model of peritoneal endometriosis is similar to cancer diseases [J]. J Exp Clin Cancer Res, 2010, 29 (1): 1-9.
  • 10Lahteenvuo JE, Lahteenvuo MT, Kivela A, et al. Vascular endothelial growth faetor-B induces myocardium specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms [J]. Circulation, 2009, 119 (6): 845-856.

共引文献61

同被引文献168

引证文献6

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部